PARAMUS,
N.J., July 10, 2024 /PRNewswire/ -- NS Pharma,
Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon
Shinyaku), announced that its Board of Directors has appointed a
new President at its US headquarters. Yukiteru Sugiyama, Ph.D.
replaces retiring president Tsugio
Tanaka, MSc as of June 30,
2024.
"As president, it is my mission to maintain
heightened levels of empathy at NS Pharma."
Sugiyama received a doctorate degree in organic chemistry from
Nagoya University in 1996. From
1996 until 2007, he worked in research and clinical development
with Nippon Shinyaku in Japan,
focusing on structural chemistry and blood cancer therapies. In
2007, he transitioned to the commercial division within the
company.
In 2020, during the COVID-19 pandemic, Sugiyama transferred to
NS Pharma in the US to work as assistant vice president overseeing
commercial functions for VILTEPSO®(viltolarsen). In
total, Sugiyama has worked for 28 years at Nippon Shinyaku with
progressive levels of responsibility.
"Having served in both our science and patient focused fields, I
have come to understand that having empathy for the patient is
critical in the development of therapies to treat rare diseases,"
Sugiyama explained. "As president, it is my mission to maintain
heightened levels of empathy at NS Pharma, and to enhance
transparency between all stakeholders."
Sugiyama will lead the company through the next phases of
clinical and commercial development for VILTEPSO and CAP-1002
(through a partnership with Capricor Therapeutics) – for the
treatment of Duchenne muscular dystrophy (Duchenne). NS Pharma is
also currently working on an exon 44 skipping therapy (Phase 2) and
an exon 50 skipping therapy (Phase 1/2) for Duchenne, a selective
JAK1 inhibition therapy for the treatment of eosinophilic
granulomatosis with polyangiitis (EGPA), as well as several
preclinical neurological therapies.
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly
owned subsidiary of Nippon Shinyaku Co., Ltd. NS Pharma is a
registered trademark of the Nippon Shinyaku Co., Ltd. For more
information, please visit nspharma.com.
US Media Contact:
media@nspharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ns-pharma-appoints-new-president-to-oversee-next-phases-of-orphan-drug-clinical-development-and-commercialization-302191606.html
SOURCE NS Pharma, Inc.